enGene to Present at the Jefferies Global Healthcare Conference
29 Maio 2024 - 8:30AM
Business Wire
enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the
“Company”), a clinical-stage genetic medicines company whose
non-viral lead program EG-70 is in a pivotal study for
BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today
announced that Jason Hanson, Chief Executive Officer, will present
a corporate overview at the Jefferies Global Healthcare Conference
in New York City, on June 5, 2024, at 12:30 p.m. ET.
A live webcast of the presentation can be accessed under the
Investors section of the enGene website at
www.engene.com/presentations and will be archived there for 90
days.
About enGene
enGene is a clinical-stage biotechnology company mainstreaming
genetic medicines through the delivery of therapeutics to mucosal
tissues and other organs, with the goal of creating new ways to
address diseases with high clinical needs. enGene’s lead program is
EG-70 for patients with non-muscle invasive bladder cancer (NMIBC)
with carcinoma in situ (Cis) who are unresponsive or naïve to
treatment with Bacillus Calmette-Guérin (BCG) – a disease with a
high clinical burden. EG-70 is being evaluated in an ongoing Phase
2 pivotal study. EG-70 was developed using enGene’s proprietary
Dually Derivatized Oligochitosan (DDX) platform, which enables
penetration of mucosal tissues and delivery of a wide range of
sizes and types of cargo, including DNA and various forms of RNA.
For more information, visit enGene.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240529566127/en/
Investor investors@engene.com
Media media@engene.com
enGene (NASDAQ:ENGN)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
enGene (NASDAQ:ENGN)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024
